| Verified against primary record | |
| Definition | Teams drawn from different disciplines working to a common goal, with no prescribed membership[1] |
|---|---|
| English cancer practice | Every patient is listed, but cases meeting an agreed standard of care are listed without being discussed[2] |
| Independently reported | |
| Effect on management plans | Plans changed in 1.6 to 58 per cent of cases across 41 studies, which the reviewers rate as low to very low quality evidence[3] |
| Bands apply only to the rows beneath them. The reported effect is a change in the management plan, not an improvement in outcome, and the reviewers note that studies comparing plans made before and after discussion by the same physicians may overstate it. | |
Multidisciplinary care is care planned by a group of clinicians from different disciplines rather than by one. In cancer services it is formalised as a team meeting at which cases are reviewed. For a patient treated abroad, the team that plans the treatment and the clinicians who manage the consequences sit in different countries, and no standard was located that addresses that arrangement.
No prescribed membership
The generic definition is loose by design. An English workforce body describes multidisciplinary teams as teams drawn from different disciplines working to a common goal, also called interdisciplinary or multi-professional, with no single prescribed membership and the possible inclusion of service users and carers. The same document sets out the claimed benefits, including outcomes, personalised care, staff satisfaction and resource efficiency, and is unusually frank about the limits: cultural barriers, time and funding requirements, role blurring that can threaten professional identity, burnout risk, complex data sharing, context-dependence, and the warning that benefits depend on implementation and that more proactive care can produce unintended effects such as increased unplanned admissions.[1]
Where membership is prescribed, it is prescribed per service rather than in general. A national quality standard for pancreatic cancer requires that diagnosis and care be agreed by a specialist pancreatic cancer multidisciplinary team, with providers establishing pathways so that these teams review all suspected cases in partnership with local teams; the stated rationale is reduced diagnostic delay, better staging, consideration of all management options, specialist knowledge of novel treatments and trials, and access to nutrition, pain and mental health support.[4]
Not every case is discussed
A common belief about English cancer care is now out of date. Under streamlining guidance adopted from 2019, every patient is still listed at the meeting, but cases are sorted into those requiring full discussion, on grounds of clinical complexity, psycho-social issues or patient preference, and those whose needs are met by a recognised treatment protocol, which are listed but not discussed. Conditions must be met before a case can be marked not for discussion: a minimum core dataset, reported pathology and imaging, completed tests, consideration of patient preference, and a core team member having seen the patient or assessed the circumstances. Standards of care are agreed locally and signed off through tumour pathway boards, the responsible clinician and the patient make the final treatment decision, any doubt or new information returns a case to full discussion, and use is audited with quarterly review of sampled cases.[2] The approach is recommended rather than mandatory, though organisations that adopt it must follow it.
What the evidence supports
The best available synthesis measures whether the plan changed, not whether the patient did better. Across 41 studies of colorectal, lung, prostate and breast cancer, management plans changed after the team meeting in between 1.6 and 58 per cent of cases, with lung around 53 to 58 per cent, breast 42.1 per cent in one study, prostate between about 1.6 and 43 per cent, and colorectal between about 6 and 29 per cent; treatment plans changed more often than diagnostic plans. The reviewers rate the evidence as low to very low quality, note that it is mostly observational with high or serious risk of bias, and identify a specific mechanism by which the effect may be overstated, namely that studies comparing plans made before and after discussion by the same physicians are not independent measurements.[3] No point estimate should be taken from that range, and the finding should not be upgraded from a change in plan to an improvement in outcome.
Observational work on the meetings themselves suggests that quality depends on conditions rather than membership. In a study of 30 filmed weekly meetings of three cancer teams, covering 44 members and 822 coded case discussions, decision-making quality was higher where questions were asked and answered, with larger teams, gender balance and higher clinical complexity, and lower with negative socioemotional reactions, gender imbalance, logistical problems, time and workload pressure and longer meetings; decision quality, interaction, group size and case complexity all declined in the second half of meetings as time pressure rose.[5]
Streamlining itself carries risks that its proponents acknowledge. A review of the practice notes that team meetings are regarded as essential in cancer care but are time- and resource-intensive and that the effectiveness of team processes varies, and identifies potential drawbacks of streamlining including misapplied definitions of complexity, reduced interdisciplinary collaboration and bias, and that standards of care cannot be applied universally across teams and organisations.[6]
The gap in medical travel
No source was located documenting multidisciplinary review for cross-border patients, and no standard was found addressing a team whose members sit in the treatment country while follow-up sits in the home country. That absence is reported as a finding rather than filled by inference. Its practical significance is that the two functions a team meeting performs, considering all management options and distributing responsibility for the plan across several clinicians, are both weakened when the only clinician with a complete view is the one being paid to operate.
See also
- Continuity of Care, the broader construct that team review is one mechanism of
- Second Medical Opinions, the individual equivalent of putting a plan to another clinician
- Cancer Treatment Abroad, the setting in which team review is most formalised at home
- Clinical Practice Guidelines, the standards against which a team’s plan is judged
References
- Health Education England. Multidisciplinary Team Toolkit, version 1.1. First published October 2021. Verified against primary record: the toolkit was opened and its definition, claimed benefits and stated limits read. Retrieved 10 October 2026.
- NHS England and NHS Improvement, NHS Cancer Programme. Streamlining Multi-Disciplinary Team Meetings: Guidance for Cancer Alliances. August 2019. Verified against primary record: the guidance was opened and the triage model, the conditions for marking a case not for discussion, and the audit requirement read. Retrieved 10 October 2026.
- Koco L, Weekenstroo HHA, Lambregts DMJ, Sedelaar JPM, Prokop M, Fuetterer JJ, Mann RM. The Effects of Multidisciplinary Team Meetings on Clinical Practice for Colorectal, Lung, Prostate and Breast Cancer: A Systematic Review. Cancers 2021;13(16):4159, 18 August 2021. Verified against primary record: the article was opened and the reported ranges by tumour site, the quality rating and the stated bias mechanism read. Retrieved 10 October 2026.
- National Institute for Health and Care Excellence. Quality standard QS177, quality statement 1: specialist pancreatic cancer multidisciplinary teams. No publication date on the fetched content; cites guideline NG85 recommendations. Verified against primary record: the quality statement was opened and its requirement and rationale read. Retrieved 10 October 2026.
- Soukup T, Lamb BW, Morbi A, Shah NJ, Bali A, Asher V, Gandamihardja T, Giordano P, Darzi A, Green JSA, Sevdalis N. A multicentre cross-sectional observational study of cancer multidisciplinary teams: analysis of team decision making. Cancer Medicine 2020;9(19):7083-7099. Independently reported: the indexing record and abstract were opened and the study scale and findings read; the full text was not read. Retrieved 10 October 2026.
- Al-Hammouri T, Almeida-Magana R, Soukup T, Lamb B. Mini review on cancer multidisciplinary team meeting streamlining. Frontiers in Health Services 2024;4:1340320, 12 March 2024. Verified against primary record: the article PDF was opened and its account of the drawbacks of streamlining read. Note that it is a narrative mini review which does not report its search methods. Retrieved 10 October 2026.
Sourcing note: the effect of team review is reported only as a change in the management plan, because that is what the underlying studies measured. No source was located establishing that multidisciplinary review improves patient outcomes, and none was located documenting multidisciplinary review in a cross-border setting. Membership and quorum requirements for English cancer teams are set in separate national quality surveillance indicators and service specifications that the streamlining guidance refers to without reproducing, and which were not consulted for this entry.